Susan Hasty, Publisher
Table of Contents . . . April 26th, 1999Non-Subscriber - Summaries Only
Cancer Immunotherapy - Naked DNA Cytokine Delivery Has Immune Modulating Effects
Cancer Immunotherapy - Combination Therapy goes to Trial
Cancer Immunotherapy - Gene-Gun Therapy Pulls Trigger on Cancer
Cancer Immunotherapy - HCC Immunotherapy Could Target MAGE Gene Family
Cancer Immunotherapy - NY-ESO-1 Expression Could Be Exploited for Immunotherapy
Cancer Immunotherapy - Short-Term Interleukin Expression Attacks Cancer Cells
Cancer Immunotherapy - Trials Suggest IFN-(alpha) May Have Merit in Cancer Treatment
Bone Marrow Transplantation - T. longibrachiatum Acquired Via Gastrointestinal Tract
Coinfection - HGV Doesn't Impact IFN Efficacy
Conference Coverage (2nd Annual Vaccine) - Transcutaneous Immunization Advances in Animal Studies
Cytokines (TB) - Type 1 and 2 Cytokines Involved in TB Reactivation
Epidemiology - Cytokine Assay Aids Evaluation in Endemic Areas
Therapy (HCV) - Phase I/II Study Shows rHuIL-12 Not Effective
Cancer Immunotherapy (AACR Conference News) - Drug's Protective Effect on Lymphocytes Reported
Cirrhosis (Animal Models) - Immune System Process Could Halt Progress of Cirrhosis
Implant Rejection - New Coating Process May Prevent Implant Rejection
Cancer Immunotherapy - "Adoptive Immunotherapy for Post Transplant EBV Lymphoma."
Cancer Vaccines - "Recombinant Tumor Vaccine - CATBRM."
Chronic Lymphocytic Leukemia - "CD40-Activated B-Cell Chronic Lymphocytic Leukemia Cells for Tumor Immunotherapy: Stimulation of Allogeneic Versus Autologous T Cells Generates Different Types of Effector Cells."